{"count": 19, "results": [{"_id": "33081077", "pmid": 33081077, "pmcid": "PMC7602813", "title": "Metformin Reduces NGF-Induced Tumour Promoter Effects in Epithelial Ovarian Cancer Cells", "journal": "Pharmaceuticals (Basel)", "authors": ["Garrido MP", "Salvatierra R", "Valenzuela-Valderrama M", "Vallejos C", "Bruneau N", "Hernández A", "Vega M", "Selman A", "Quest AFG", "Romero C"], "date": "2020-10-16T00:00:00Z", "doi": "10.3390/ph13100315", "meta_date_publication": "2020 Oct 16", "meta_volume": "13", "meta_issue": "10", "meta_pages": "", "score": 50290.855, "text_hl": "This mechanism may explain how @<m>DISEASE_Carcinoma_Ovarian_Epithelial</m> @DISEASE_MESH:D000077216 @@@EOC@@@ cells become resistant to @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ treatment. ", "citations": {"NLM": "Garrido MP, Salvatierra R, Valenzuela-Valderrama M, Vallejos C, Bruneau N, Hernández A, Vega M, Selman A, Quest AFG, Romero C. Metformin Reduces NGF-Induced Tumour Promoter Effects in Epithelial Ovarian Cancer Cells Pharmaceuticals (Basel). 2020 Oct 16;13(10):. PMID: 33081077", "BibTeX": "@article{33081077, title={Metformin Reduces NGF-Induced Tumour Promoter Effects in Epithelial Ovarian Cancer Cells}, author={Garrido MP and Salvatierra R and Valenzuela-Valderrama M and Vallejos C and Bruneau N and Hernández A and Vega M and Selman A and Quest AFG and Romero C}, journal={Pharmaceuticals (Basel)}, volume={13}, number={10}}"}}, {"_id": "32456076", "pmid": 32456076, "pmcid": "PMC7281007", "title": "TOM40 Inhibits Ovarian Cancer Cell Growth by Modulating Mitochondrial Function Including Intracellular ATP and ROS Levels", "journal": "Cancers (Basel)", "authors": ["Yang W", "Shin HY", "Cho H", "Chung JY", "Lee EJ", "Kim JH", "Kang ES"], "date": "2020-05-22T00:00:00Z", "doi": "10.3390/cancers12051329", "meta_date_publication": "2020 May 22", "meta_volume": "12", "meta_issue": "5", "meta_pages": "", "score": 50280.992, "text_hl": "...2.5. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Inhibits the Proliferation of @GENE_TOMM40 @GENE_10452 @@@TOM40@@@-Overexpressing @<m>DISEASE_Carcinoma_Ovarian_Epithelial</m> @DISEASE_MESH:D000077216 @@@EOC@@@ Cells in an @GENE_PRKAA1 @GENE_5562 @@@AMPK@@@-Independent Manner", "citations": {"NLM": "Yang W, Shin HY, Cho H, Chung JY, Lee EJ, Kim JH, Kang ES. TOM40 Inhibits Ovarian Cancer Cell Growth by Modulating Mitochondrial Function Including Intracellular ATP and ROS Levels Cancers (Basel). 2020 May 22;12(5):. PMID: 32456076", "BibTeX": "@article{32456076, title={TOM40 Inhibits Ovarian Cancer Cell Growth by Modulating Mitochondrial Function Including Intracellular ATP and ROS Levels}, author={Yang W and Shin HY and Cho H and Chung JY and Lee EJ and Kim JH and Kang ES}, journal={Cancers (Basel)}, volume={12}, number={5}}"}}, {"_id": "34638899", "pmid": 34638899, "pmcid": "PMC8508816", "title": "Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines", "journal": "Int J Mol Sci", "authors": ["Gralewska P", "Gajek A", "Marczak A", "Rogalska A"], "date": "2021-09-29T00:00:00Z", "doi": "10.3390/ijms221910557", "meta_date_publication": "2021 Sep 29", "meta_volume": "22", "meta_issue": "19", "meta_pages": "", "score": 50279.81, "text_hl": "Taken together, the results support the use of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ to sensitize @<m>DISEASE_Carcinoma_Ovarian_Epithelial</m> @DISEASE_MESH:D000077216 @@@EOC@@@ to @CHEMICAL_olaparib @CHEMICAL_MESH:C531550 @@@olaparib@@@ therapy.", "citations": {"NLM": "Gralewska P, Gajek A, Marczak A, Rogalska A. Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines Int J Mol Sci. 2021 Sep 29;22(19):. PMID: 34638899", "BibTeX": "@article{34638899, title={Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines}, author={Gralewska P and Gajek A and Marczak A and Rogalska A}, journal={Int J Mol Sci}, volume={22}, number={19}}"}}, {"_id": "35565427", "pmid": 35565427, "pmcid": "PMC9104826", "title": "Shifting the Soil: Metformin Treatment Decreases the Protumorigenic Tumor Microenvironment in Epithelial Ovarian Cancer", "journal": "Cancers (Basel)", "authors": ["Taylor SE", "Chan DK", "Yang D", "Bruno T", "Lieberman R", "Siddiqui J", "Soong TR", "Coffman L", "Buckanovich RJ"], "date": "2022-05-05T00:00:00Z", "doi": "10.3390/cancers14092298", "meta_date_publication": "2022 May 5", "meta_volume": "14", "meta_issue": "9", "meta_pages": "", "score": 50277.83, "text_hl": "Shifting the Soil: @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Treatment Decreases the Protumorigenic @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@Tumor@@@ Microenvironment in @<m>DISEASE_Carcinoma_Ovarian_Epithelial</m> @DISEASE_MESH:D000077216 @@@Epithelial Ovarian Cancer@@@", "citations": {"NLM": "Taylor SE, Chan DK, Yang D, Bruno T, Lieberman R, Siddiqui J, Soong TR, Coffman L, Buckanovich RJ. Shifting the Soil: Metformin Treatment Decreases the Protumorigenic Tumor Microenvironment in Epithelial Ovarian Cancer Cancers (Basel). 2022 May 5;14(9):. PMID: 35565427", "BibTeX": "@article{35565427, title={Shifting the Soil: Metformin Treatment Decreases the Protumorigenic Tumor Microenvironment in Epithelial Ovarian Cancer}, author={Taylor SE and Chan DK and Yang D and Bruno T and Lieberman R and Siddiqui J and Soong TR and Coffman L and Buckanovich RJ}, journal={Cancers (Basel)}, volume={14}, number={9}}"}}, {"_id": "33404163", "pmid": 33404163, "title": "Roles of metformin-mediated girdin expression in metastasis of epithelial ovarian cancer.", "journal": "Cell Biol Int", "authors": ["Dang J", "Gao J", "Ma F", "Luo Y", "Wang J", "Wang D", "Li W", "Sun H", "Li L", "Liu X", "Hu D", "Jin Z"], "date": "2021-05-01T00:00:00Z", "doi": "10.1002/cbin.11547", "meta_date_publication": "2021 May", "meta_volume": "45", "meta_issue": "5", "meta_pages": "1030-1037", "score": 50267.62, "text_hl": "Antimetastatic effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ has been documented in @<m>DISEASE_Carcinoma_Ovarian_Epithelial</m> @DISEASE_MESH:D000077216 @@@epithelial ovarian cancer@@@ (@<m>DISEASE_Carcinoma_Ovarian_Epithelial</m> @DISEASE_MESH:D000077216 @@@EOC@@@). ", "citations": {"NLM": "Dang J, Gao J, Ma F, Luo Y, Wang J, Wang D, Li W, Sun H, Li L, Liu X, Hu D, Jin Z. Roles of metformin-mediated girdin expression in metastasis of epithelial ovarian cancer. Cell Biol Int. 2021 May;45(5):1030-1037. PMID: 33404163", "BibTeX": "@article{33404163, title={Roles of metformin-mediated girdin expression in metastasis of epithelial ovarian cancer.}, author={Dang J and Gao J and Ma F and Luo Y and Wang J and Wang D and Li W and Sun H and Li L and Liu X and Hu D and Jin Z}, journal={Cell Biol Int}, volume={45}, number={5}, pages={1030-1037}}"}}, {"_id": "32146550", "pmid": 32146550, "pmcid": "PMC7497683", "title": "Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer", "journal": "Invest New Drugs", "authors": ["Broekman KE", "Hof MAJ", "Touw DJ", "Gietema JA", "Nijman HW", "Lefrandt JD", "Reyners AKL", "Jalving M"], "date": "2020-10-01T00:00:00Z", "doi": "10.1007/s10637-020-00920-7", "meta_date_publication": "2020 Oct", "meta_volume": "38", "meta_issue": "5", "meta_pages": "1454-1462", "score": 50257.855, "text_hl": "Phase I study of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in combination with @CHEMICAL_Carboplatin @CHEMICAL_MESH:D016190 @@@carboplatin@@@/@CHEMICAL_Paclitaxel @CHEMICAL_MESH:D017239 @@@paclitaxel@@@ chemotherapy in @SPECIES_9606 @@@patients@@@ with advanced @<m>DISEASE_Carcinoma_Ovarian_Epithelial</m> @DISEASE_MESH:D000077216 @@@epithelial ovarian cancer@@@", "citations": {"NLM": "Broekman KE, Hof MAJ, Touw DJ, Gietema JA, Nijman HW, Lefrandt JD, Reyners AKL, Jalving M. Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer Invest New Drugs. 2020 Oct;38(5):1454-1462. PMID: 32146550", "BibTeX": "@article{32146550, title={Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer}, author={Broekman KE and Hof MAJ and Touw DJ and Gietema JA and Nijman HW and Lefrandt JD and Reyners AKL and Jalving M}, journal={Invest New Drugs}, volume={38}, number={5}, pages={1454-1462}}"}}, {"_id": "34548861", "pmid": 34548861, "pmcid": "PMC8434841", "title": "Effect of metformin on irinotecan-induced cell cycle arrest in colorectal cancer cell lines HCT116 and SW480", "journal": "Int J Health Sci (Qassim)", "authors": ["Khader EI", "Ismail WW", "Mhaidat NM", "Alqudah MA"], "date": "2021-09-01T00:00:00Z", "meta_date_publication": "2021 Sep-Oct", "meta_volume": "15", "meta_issue": "5", "meta_pages": "34-41", "score": 50257.457, "text_hl": "The results of evaluating the chemo-sensitizing effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on resistant @<m>DISEASE_Carcinoma_Ovarian_Epithelial</m> @DISEASE_MESH:D000077216 @@@epithelial ovarian cancer@@@ (@<m>DISEASE_Carcinoma_Ovarian_Epithelial</m> @DISEASE_MESH:D000077216 @@@EOC@@@) cell lines support our findings by reducing significantly @<m>DISEASE_Carcinoma_Ovarian_Epithelial</m> @DISEASE_MESH:D000077216 @@@EOC@@@ cells viability up to 40%.", "citations": {"NLM": "Khader EI, Ismail WW, Mhaidat NM, Alqudah MA. Effect of metformin on irinotecan-induced cell cycle arrest in colorectal cancer cell lines HCT116 and SW480 Int J Health Sci (Qassim). 2021 Sep-Oct;15(5):34-41. PMID: 34548861", "BibTeX": "@article{34548861, title={Effect of metformin on irinotecan-induced cell cycle arrest in colorectal cancer cell lines HCT116 and SW480}, author={Khader EI and Ismail WW and Mhaidat NM and Alqudah MA}, journal={Int J Health Sci (Qassim)}, volume={15}, number={5}, pages={34-41}}"}}, {"_id": "32369446", "pmid": 32369446, "title": "Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer.", "journal": "JCI Insight", "authors": ["Brown JR", "Chan DK", "Shank JJ", "Griffith KA", "Fan H", "Szulawski R", "Yang K", "Reynolds RK", "Johnston C", "McLean K", "Uppal S", "Liu JR", "Cabrera L", "Taylor SE", "Orr BC", "Modugno F", "Mehta P", "Bregenzer M", "Mehta G", "Shen H", "Coffman LG", "Buckanovich RJ"], "date": "2020-06-04T00:00:00Z", "doi": "10.1172/jci.insight.133247", "meta_date_publication": "2020 Jun 4", "meta_volume": "5", "meta_issue": "11", "meta_pages": "", "score": 50257.43, "text_hl": "As part of a phase II trial, we evaluated the impact of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on CSC number and on @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@carcinoma@@@-associated mesenchymal stem cells (CA-MSCs) and clinical outcomes in nondiabetic @SPECIES_9606 @@@patients@@@ with advanced-stage @<m>DISEASE_Carcinoma_Ovarian_Epithelial</m> @DISEASE_MESH:D000077216 @@@epithelial ovarian cancer@@@ (@<m>DISEASE_Carcinoma_Ovarian_Epithelial</m> @DISEASE_MESH:D000077216 @@@EOC@@@).METHODSThirty-eight @SPECIES_9606 @@@patients@@@ with stage IIC (n = 1)/III (n = 25)/IV (n = 12) @<m>DISEASE_Carcinoma_Ovarian_Epithelial</m> @DISEASE_MESH:D000077216 @@@EOC@@@ were treated with either (a) neoadjuvant @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, debulking surgery, and adjuvant chemotherapy plus @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ or (b) neoadjuvant chemotherapy and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, interval debulking surgery, and adjuvant chemotherapy plus @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@. ", "citations": {"NLM": "Brown JR, Chan DK, Shank JJ, Griffith KA, Fan H, Szulawski R, Yang K, Reynolds RK, Johnston C, McLean K, Uppal S, Liu JR, Cabrera L, Taylor SE, Orr BC, Modugno F, Mehta P, Bregenzer M, Mehta G, Shen H, Coffman LG, Buckanovich RJ. Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. JCI Insight. 2020 Jun 4;5(11):. PMID: 32369446", "BibTeX": "@article{32369446, title={Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer.}, author={Brown JR and Chan DK and Shank JJ and Griffith KA and Fan H and Szulawski R and Yang K and Reynolds RK and Johnston C and McLean K and Uppal S and Liu JR and Cabrera L and Taylor SE and Orr BC and Modugno F and Mehta P and Bregenzer M and Mehta G and Shen H and Coffman LG and Buckanovich RJ}, journal={JCI Insight}, volume={5}, number={11}}"}}, {"_id": "29774060", "pmid": 29774060, "pmcid": "PMC5949935", "title": "Metformin prevents nerve growth factor-dependent proliferative and proangiogenic effects in epithelial ovarian cancer cells and endothelial cells", "journal": "Ther Adv Med Oncol", "authors": ["Garrido MP", "Vera C", "Vega M", "Quest AFG", "Romero C"], "date": "2018-05-04T00:00:00Z", "doi": "10.1177/1758835918770984", "meta_date_publication": "2018", "meta_volume": "10", "meta_issue": "", "meta_pages": "1758835918770984", "score": 50083.74, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ prevents @GENE_NGF @GENE_4803 @@@nerve growth factor@@@-dependent proliferative and proangiogenic effects in @<m>DISEASE_Carcinoma_Ovarian_Epithelial</m> @DISEASE_MESH:D000077216 @@@epithelial ovarian cancer@@@ cells and endothelial cells", "citations": {"NLM": "Garrido MP, Vera C, Vega M, Quest AFG, Romero C. Metformin prevents nerve growth factor-dependent proliferative and proangiogenic effects in epithelial ovarian cancer cells and endothelial cells Ther Adv Med Oncol. 2018;10():1758835918770984. PMID: 29774060", "BibTeX": "@article{29774060, title={Metformin prevents nerve growth factor-dependent proliferative and proangiogenic effects in epithelial ovarian cancer cells and endothelial cells}, author={Garrido MP and Vera C and Vega M and Quest AFG and Romero C}, journal={Ther Adv Med Oncol}, volume={10}, pages={1758835918770984}}"}}, {"_id": "26266765", "pmid": 26266765, "title": "Metformin and epithelial ovarian cancer therapeutics.", "journal": "Cell Oncol (Dordr)", "authors": ["Patel S", "Kumar L", "Singh N"], "date": "2015-10-01T00:00:00Z", "doi": "10.1007/s13402-015-0235-7", "meta_date_publication": "2015 Oct", "meta_volume": "38", "meta_issue": "5", "meta_pages": "365-75", "score": 50082.96, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ and @<m>DISEASE_Carcinoma_Ovarian_Epithelial</m> @DISEASE_MESH:D000077216 @@@epithelial ovarian cancer@@@ therapeutics.", "citations": {"NLM": "Patel S, Kumar L, Singh N. Metformin and epithelial ovarian cancer therapeutics. Cell Oncol (Dordr). 2015 Oct;38(5):365-75. PMID: 26266765", "BibTeX": "@article{26266765, title={Metformin and epithelial ovarian cancer therapeutics.}, author={Patel S and Kumar L and Singh N}, journal={Cell Oncol (Dordr)}, volume={38}, number={5}, pages={365-75}}"}}]}